Athersys, Inc presented data (5/14/10) supporting its MultiStem(NYSE:R) programs. The findings were described in a series of presentations by leading researchers, clinicians and collaborators at their annual Investor Research & Development Day held in NYC, NY.
Athersys is currently conducting a phase I clinical trial of MultiStem in patients who have suffered from an acute myocardial infarction (AMI). Enrollment in this trial was completed in 2/10 and initial data and results are expected mid-summer,
- New and previously published preclinical data were presented outlining MultiStem’s demonstrated ability to deliver therapeutic benefits in cardiovascular disease models of AMI, including increasing heart function, providing a cardio-protective effect, reducing scar size, promoting angiogenesis, vasculogenesis by regulating and reducing inflammatory cell migration into the heart,
- MultiStem can provide benefits for the treatment of peripheral vascular disease by promoting angiogenesis, resulting in increased vessel density and improved blood flow, reduced necrosis and improved exercise performance.
Presentations provided an overview of Athersys’ relevant therapeutic target markets, a description of the results of internal and collaborative research and clinical programs, and an outline of the development path for certain programs. An audio webcast of the event is available on the Athersys website at http://www.athersys.com/ and will be archived for two weeks.